Clinical Trial Search

Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…

Primary: Metabolic Syndrome Components — -2.7; 4.7 mmHg — p=0.013

Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period — 0.022; 0.213; 0.173; 0.250 Liter…

Primary: Safe Usability of the VIBEX MTX Device for Subcutaneous (SC) Self-injection With Methotrexate (MTX) in Adult Patients With Rheumatoid Arthritis (RA) as Demonstrated by…

Primary: Time to Treatment Failure — 0; 8 participants

Primary: Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication — 0; 0 Participants

Primary: Progression-free Survival (PFS) Time: Investigator Read — 6.4; 5.6; 5.7 months — p=0.885

Primary: Change From Baseline in DAS28-CRP at 12 Weeks — -1.147; -0.813; -1.237; -0.907 units on a scale

Primary: Viral Load: Incidence of Sustained Virologic Response (SVR) — 4; 7; 2; 4 participants

Primary: Absolute C-reactive Protein (CRP) Values at Day 98 - As Treated Population — 12.85; 14.25; 21.85; 16.60 mg/L

Primary: Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 1 — 500.2; 495.8; 499.5; 468.3 Microns

Primary: Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate — NA mg/day

Primary: Number of Participants With Dose-limiting Toxicity (DLT) — 0; 0; 1; 2 participants

Primary: Safety: Adverse Events, Adverse Drug Reactions — 75.0; 66.7; 35.7; 46.2 percentage of incidences

Primary: Change in DAS28-CRP After 12 Weeks of Treatment — -1.0; -1.0 scores — p=0.9334